Skip to main content

Table 6 Results of robustness of 100% level solution

From: An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Variation of parameterLamivudineDolutegravir
RTPeak areaUSP plate countUSP tailing factor% assayRTPeak areaUSP plate countUSP tailing factor% assay
Mobile phase ratio (± 1 ml)14:863.34910,691,54071721.0699.925.0684,144,87899431.06100.3
15:853.3410,699,76871461.051005.0654,131,55799231.05100
16:843.34810,713,74671201.06100.15.0684,155,62310,0221.06100.9
Flow rate (± 0.1 ml)0.7 ml3.81710,734,38972521.7100.35.7864,912,66110,6711.06107.5
0.8 ml3.3410,699,76871461.051005.0654,131,30799231.05100
0.9 ml2.9839,614,16566961.789.854.513,708,00396171.0596.91
Maximum wavelength (± 2 nm)2563.34710,699,76973211.061005.0654,131,30799841.06100.6
2583.3410,699,76871461.051005.0654,131,30799231.05100
2603.34910,691,540729610.599.925.0684,144,85196361.06197.1
  1. RT retention time; slight change in method parameter could not affect the USP plate count and taliling factor